Virpax Pharmaceuticals

Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has reported encouraging results from a minipig Dose Range Finding (DRF) study for Probudur, its long-acting liposomal bupivacaine injection. Designed to provide …

Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation Read More

Virpax Pharmaceuticals

Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), a division …

Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation Read More
Ocugen

Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received orphan medicinal product designation from the European Medicines Agency (EMA) for OCU410ST, a promising treatment for ABCA4-associated retinopathies including Stargardt disease, …

Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment Read More